GenSight Biologics announced the appointment of Mrs. Laurence Rodriguez, as new Chief Executive Officer. Laurence Rodriguez has over 30 years? experience in the life sciences industry, including 13 years in the rare diseases business at Sanofi Genzyme, where she held a range of executive roles.

As Head of the Rare Diseases & Rare Blood Disorders unit at Sanofi Genzyme, she oversaw the successful launch of various rare disease products developed or acquired by the Company. She joined GenSight Biologics in May 2021 as Head of Operations for France. She handled the early access program in preparation for LUMEVOQ's commercialization and created strong and trustworthy relationships with the various stakeholders.

Laurence Rodriguez holds a Bachelor?s degree in Nutrition and Biochemistry and a Master?s degree from Sciences Po, Paris, France, and completed an Organization Leadership Program at the Harvard Business School. The board of directors thanked Bernard Gilly, co-founder of the Company in 2012 together with Pr. José-Alain Sahel, for his many years of dedication to the Company and his essential contribution to make LUMEVOQ a life changing therapy.

He will remain a director of the Company while he no longer assumes operational responsibilities.